1. Home
  2. MXCT vs PRTC Comparison

MXCT vs PRTC Comparison

Compare MXCT & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MXCT
  • PRTC
  • Stock Information
  • Founded
  • MXCT 1999
  • PRTC 2015
  • Country
  • MXCT United States
  • PRTC United States
  • Employees
  • MXCT N/A
  • PRTC N/A
  • Industry
  • MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • PRTC Biotechnology: Pharmaceutical Preparations
  • Sector
  • MXCT Health Care
  • PRTC Health Care
  • Exchange
  • MXCT Nasdaq
  • PRTC Nasdaq
  • Market Cap
  • MXCT 361.8M
  • PRTC 431.1M
  • IPO Year
  • MXCT 2021
  • PRTC N/A
  • Fundamental
  • Price
  • MXCT $2.71
  • PRTC $19.10
  • Analyst Decision
  • MXCT Strong Buy
  • PRTC Buy
  • Analyst Count
  • MXCT 2
  • PRTC 1
  • Target Price
  • MXCT $10.00
  • PRTC $45.00
  • AVG Volume (30 Days)
  • MXCT 701.5K
  • PRTC 2.5K
  • Earning Date
  • MXCT 03-11-2025
  • PRTC 04-24-2025
  • Dividend Yield
  • MXCT N/A
  • PRTC N/A
  • EPS Growth
  • MXCT N/A
  • PRTC N/A
  • EPS
  • MXCT N/A
  • PRTC N/A
  • Revenue
  • MXCT $38,627,000.00
  • PRTC $468,000.00
  • Revenue This Year
  • MXCT $20.01
  • PRTC N/A
  • Revenue Next Year
  • MXCT $26.64
  • PRTC $160.00
  • P/E Ratio
  • MXCT N/A
  • PRTC N/A
  • Revenue Growth
  • MXCT N/A
  • PRTC N/A
  • 52 Week Low
  • MXCT $2.62
  • PRTC $16.30
  • 52 Week High
  • MXCT $5.26
  • PRTC $34.00
  • Technical
  • Relative Strength Index (RSI)
  • MXCT 27.30
  • PRTC 58.88
  • Support Level
  • MXCT $2.62
  • PRTC $16.30
  • Resistance Level
  • MXCT $3.17
  • PRTC $19.78
  • Average True Range (ATR)
  • MXCT 0.17
  • PRTC 0.46
  • MACD
  • MXCT -0.02
  • PRTC 0.30
  • Stochastic Oscillator
  • MXCT 11.27
  • PRTC 80.46

About MXCT MaxCyte Inc.

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

About PRTC PureTech Health plc

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.

Share on Social Networks: